07:00 , May 30, 2016 |  BioCentury  |  Strategy

Taking Takeda global

Two years after joining Takeda Pharmaceutical Co. Ltd., Christophe Weber has narrowed the company's therapeutic focus, expanded the executive team and reorganized its approach to market with the aim of transforming the company into a...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Company News

Takeda, AstraZeneca deal

AstraZeneca will acquire Takeda’s core respiratory business, including Daliresp roflumilast, Alvesco ciclesonide, Omnaris ciclesonide nasal spray and seven undisclosed early pipeline products. Takeda will receive a $575 million upfront payment and will...
02:33 , Dec 17, 2015 |  BC Extra  |  Top Story

AZ bulks up China operations, respiratory portfolio

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Wednesday it would build up its presence in China and acquire a global respiratory portfolio from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for $575 million in cash. AZ's growth in China...
08:00 , Dec 16, 2013 |  BioCentury  |  Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
07:00 , Sep 3, 2012 |  BC Week In Review  |  Company News

Elevation Pharmaceuticals, Dainippon Sumitomo deal

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary will acquire Elevation for $100 million up front and up to $300 million in development and commercial milestones related to chronic obstructive pulmonary disease (COPD) product EP-101. Elevation is...
00:19 , Aug 31, 2012 |  BC Extra  |  Company News

Sunovion to acquire Elevation

The Sunovion Pharmaceuticals Inc. subsidiary of Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506) will acquire Elevation Pharmaceuticals Inc. (San Diego, Calif.) for $100 million up front and up to $300 million in development and commercial...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

Ciclesonide HFA: Phase III data

A double-blind, U.S. Phase III trial in 1,111 patients aged 12 and older showed that once-daily 74 and 148 µg ciclesonide HFA for 6 months each met the primary endpoint of significantly improving reflective TNSS...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Clinical News

Omnaris HF ciclesonide: Preliminary Phase III data

Preliminary data from a Phase III trial in 671 patients ages 12 and up showed that 80 and 160 µg/day Omnaris HFA met the primary endpoint of significantly reducing reflective TNSS averaged over the...
07:00 , May 4, 2009 |  BC Week In Review  |  Clinical News

Ciclesonide nasal aerosol: Preliminary Phase III data

Preliminary data from a double-blind trial in 707 adult and adolescent patients >=13 years old showed that 80 or 160 ug/day Omnaris HFA met the primary endpoint of significantly reducing the 24-hour reflective TNSS vs....
01:32 , Apr 28, 2009 |  BC Extra  |  Clinical News

Sepracor up after allergic rhinitis data

Sepracor Inc. (NASDAQ:SEPR) gained $0.74 to $14.09 on Monday after preliminary data showed Omnaris HFA ciclesonide met the primary endpoint of significantly reducing the 24-hour reflective total nasal symptom score (TNSS) vs. placebo in a...